NOVO NORDISK AS VORMALS NOVO
SymbolNONOF

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Novo Nordisk A/S: Director/PDMR Shareholding

2009-10-30 11:02 ET - News Release

BAGSVAERD, DENMARK -- (MARKET WIRE) -- 10/30/09

Trading in Novo Nordisk shares by board members, executives and associated persons as reported to Novo Nordisk on 29 October 2009


In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Please find below a statement of such trading in shares issued by Novo Nordisk. 


+-------------------------------------------------------------------+
| Name                            | Kurt Anker Nielsen              |
|---------------------------------+---------------------------------|
| Reason for reporting            | Member of the Board of          |
|                                 | Directors                       |
|---------------------------------+---------------------------------|
| Financial instrument and ID     | Novo Nordisk B DK006010261      |
| code                            |                                 |
|---------------------------------+---------------------------------|
| Type of transaction             | Donation of shares (Gift)       |
|---------------------------------+---------------------------------|
| Date of transaction             | 29 October 2009                 |
|---------------------------------+---------------------------------|
| Place of transaction            | NASDAQ OMX Copenhagen           |
|---------------------------------+---------------------------------|
| Volume of transaction           | 200 shares                      |
|---------------------------------+---------------------------------|
| Total value of transaction      | DKK 63,200                      |
+-------------------------------------------------------------------+

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.